Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Gains from Investment Securities (2021 - 2025)

Historic Gains from Investment Securities for Prime Medicine (PRME) over the last 5 years, with Q1 2025 value amounting to $83.8 million.

  • Prime Medicine's Gains from Investment Securities rose 8639.59% to $83.8 million in Q1 2025 from the same period last year, while for Sep 2025 it was $83.8 million, marking a year-over-year increase of 8639.59%. This contributed to the annual value of $44.9 million for FY2024, which is 127626.34% up from last year.
  • Prime Medicine's Gains from Investment Securities amounted to $83.8 million in Q1 2025, which was up 8639.59% from $44.9 million recorded in Q1 2024.
  • Over the past 5 years, Prime Medicine's Gains from Investment Securities peaked at $83.8 million during Q1 2025, and registered a low of -$1.7 million during Q1 2023.
  • For the 5-year period, Prime Medicine's Gains from Investment Securities averaged around $23.2 million, with its median value being $5.0 million (2023).
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first crashed by 8262.0% in 2023, then soared by 274168.14% in 2024.
  • Prime Medicine's Gains from Investment Securities (Quarter) stood at $2.2 million in 2021, then crashed by 99.21% to $17000.0 in 2022, then soared by 29111.76% to $5.0 million in 2023, then skyrocketed by 804.85% to $44.9 million in 2024, then skyrocketed by 86.4% to $83.8 million in 2025.
  • Its last three reported values are $83.8 million in Q1 2025, $44.9 million for Q1 2024, and $5.0 million during Q2 2023.